

500 Chipeta Way Salt Lake City, UT 84108-1221 phone: 801-583-2787 | toll free: 800-242-2787 fax: 801-584-5249 | aruplab.com

THIS IS NOT A TEST REQUEST FORM. Please complete and submit with the test request form or electronic packing list.

EXOME SEQUENCING INTAKE FORM

Failure to provide required information for exome testing will result in a suboptimal clinical report and delays in testing.

RE	EQUIRED for Ex	come Sequencing (ARUP test code 3016583):				
1.	Proband Patient Na	me: Date of Birth:				
2.	Suspected Clinical Diagnosis:					
Pro		detailing the patient's phenotype/relevant previous testing/family history or complete the Additional Clinical d in this document.				
3.	Parental/familial control samples (RECOMMENDED; ARUP test code 3016589). Submit comparator samples within 7 days of the proband's sample.					
	a. Maternal Last	Name, First Name:				
	Date of birth:	Clinically affected? \square No \square Yes:				
		lame, First Name:				
		Clinically affected? □ No □ Yes:				
	c. Additional Familial Control (if applicable) Name:					
		pand:				
	Date of birth:	Clinically affected? □ No □ Yes:				

Ordering Provider Attestation of Informed Consent (signature required below)

Test Purpose and Description

The purpose of exome sequencing is to identify the gene variant(s) causing a suspected Mendelian genetic condition. Testing requires drawing 2 mL of blood from which the DNA is extracted. DNA codes for genes. Most of the patient's genes will be sequenced.

Thousands of DNA variants will be detected by sequencing. DNA variants may be disease causing or harmless; however, the effect of many DNA variants is currently unknown.

Ordering Considerations

Participation in exome sequencing is voluntary. Genetic counseling is recommended before and following this complex test.

The chance a cause for the patient's medical issue(s) can be determined using this test varies and is influenced by the specific clinical features present. Diagnostic rates are highest when biological parents' samples are included as comparators for exome sequencing. Parental sequence data is used to identify de novo (new) changes in the patient's DNA, not found in either parent, that could explain the patient's disorder.

It is important that the familial biological relationships are correctly stated because undisclosed adoption or uncertain paternity will cause confusion and decrease the chance of identifying the causative disease variant.

Exome sequencing may identify genetic findings unrelated to the original reason for testing such as:

Predict another family member has, is at risk for, or is a carrier of an unsuspected genetic condition

- Reveal nonpaternity (the person stated to be the biological father is not, in fact, the biological father)
- · Indicate the biological parents of the patient are close blood relatives (consanguineous)

Reporting of Results

Results are generally available in 3-4 weeks. Variants that are known or suspected to be causative for the patient's medical issues are reported.

All variants identified in the patient that are related to the patient's primary disorder will be tested in familial controls. The status of all primary variants tested in controls will be indicated on the proband's report.

Candidate variants that are not known to be causative for the patient's medical issues, such as de novo variants (not inherited from either parent) or variants inherited from both parents in the same gene, may be reported even if the function of the gene is unknown.

Variants in genes unrelated to the patient's medical condition are not usually reported except for disease-causing secondary findings (see the Secondary Findings section below).

Because genetic knowledge is advancing at a rapid pace, reanalysis of exome sequencing data should be considered 12-18 months after testing is complete if a cause for the patient's condition was not determined. ARUP will perform reanalysis (ARUP test code 3001457) of exome data. If the report is amended, the ordering client will receive an updated report.

Limitations

Although genetic test results are usually accurate, several sources of error are possible, including clinical misdiagnosis of a condition, sample mislabeling or contamination, transfusion, bone marrow transplantation, maternal cell contamination of cord blood samples, or inaccurate information regarding biological relationships. If biological relationships are inaccurately reported, it could lead to an incorrect diagnosis or inconclusive result. ARUP will contact the referring provider if nonpaternity and/or consanguinity is detected but that information will not be included in the patient's report.

Often, exome sequencing is not able to identify the cause of a patient's medical issues. This does not exclude the possibility that the patient has a genetic condition. Some disease-causing variants are in genes with unknown function while others may not be identifiable using this test. Examples of variants not detectable with this test include large gene deletion/duplications, variants occurring outside of the coding region and intron-exon boundaries, chromosome rearrangements, inversions, methylation abnormalities, and those causing repeat disorders. This test does not include sequencing of the mitochondrial genome.

Secondary Findings

The American College of Medical Genetics and Genomics (ACMG) recommends reporting disease-causing variants in specific genes that increase the risk for developing cancer, cardiovascular issues, metabolic disorders, problems with anesthesia, retinopathy, and other conditions where monitoring or early treatment may be available. Please refer to the latest version of the ACMG recommendations for reporting secondary findings in clinical exome sequencing for a list of genes and associated disorders tested. Additional medically actionable variants in non-ACMG genes may be reported at ARUP's discretion.

If a patient has symptoms of a condition related to an ACMG recommended gene, separate testing should be ordered, as coverage of ACMG genes may be incomplete. Only variants in ACMG genes identified by routine exome sequencing are reported. Single disease-causing variants in recessive ACMG genes are not reported.

To receive secondary findings about the patient, the patient (or their legal guardian) would need to choose to receive this information by

selecting the "opt in" option on this intake form. Familial controls who undergo exome sequencing and desire a full analysis and report of their secondary findings must select the "opt in" option on this intake form and will incur a separate fee. Secondary findings will be reported for familial controls who elect to receive this information regardless of whether the finding was also identified in the patient. Parental inheritance of secondary findings identified in the patient will only be included in the patient's report if the positive parent also opts to receive secondary findings.

If a disease-causing genetic variant is identified, insurance rates, the ability to obtain disability and life insurance, and employability could be affected. The Genetic Information Nondiscrimination Act of 2008 extends some protections against genetic discrimination (genome.gov/10002328). All test results are released to the ordering healthcare provider and those parties entitled to them by federal, state, and local laws.

Access to Sequence Data/Data Sharing/Sample Storage

ARUP Laboratories will have access to the patient's sequence data from exome sequencing. Your healthcare provider and the hospital that submitted the test to ARUP can also request a copy of the sequence data.

Because ARUP is not a storage facility, most samples are discarded after testing is completed. Some samples may be stored indefinitely for test validation or education purposes after personal identifiers are removed. You may request disposal of your sample by calling ARUP Laboratories at 800-242-2787 ext. 3301.

In cooperation with the National Institutes of Health's effort to improve understanding of specific genetic variants, ARUP submits HIPAA-compliant, deidentified (cannot be traced back to the patient) genetic test results and health information to public databases. The confidentiality of each sample is maintained. If you prefer that your test result not be shared, call ARUP at 800-242- 2787 ext. 3301. Your deidentified information will not be disclosed to public databases after your request is received, but a separate request is required for each genetic test. Additionally, patients have the opportunity to participate in patient registries and research. To learn more, visit aruplab.com/genetics.

Ordering Healthcare Provider, Genetic Counselor: 1) I attest that I am the ordering healthcare provider or certified genetic counselor; 2) I have explained the purpose/benefits and limitations of the test to the patient or their legal guardian and all parental controls; 3) the patient/legal guardian and parental controls were offered copies of this consent document; 4) I have answered all of their questions regarding the purpose of the test, the reporting of primary and secondary findings, the use and retention of samples, and data sharing.

•	corresponding box is checked. A
L. (name(s):	
	patient or controls UNLESS the trol individuals. L. (name(s):

Exome Sequencing Additional Clinical Information:

Please provide medical records detailing the patient's phenotype/relevant previous testing/family history or complete the Additional Clinical Information section below. The ability to identify causative variant(s) for the patient's presentation is influenced by the quality of the clinical information provided.

Ordering Provider:		Provider's F	Phone:			
Practice Specialty:		Provider's F	Provider's Fax:Counselor's Phone:			
Ethnicity/Ancestry:	n American/Black	□ Asian	☐ Hispanic	☐ White	☐ Other	
Genes of Interest:						
Family History:						
PRE/PERINATAL 0000776 Congenital diaphragmatic hernia 0001627 Congenital heart defect 0000476 Cystic hygroma 0002084 Encephalocele 0007430 Generalized edema 0001789 Hydrops fetalis 0010880 Increased nuchal translucency 0001511 Intrauterine growth restriction 0002475 Myelomeningocele/spina bifida 0001562 Oligohydramnios 0001539 Omphalocele 0001561 Polyhydramnios 0001622 Prematurity-GA at birth	□ 0002119 Ve □	□ 0002126 Polymicrogyria □ 0002119 Ventriculomegaly □ Image: Problem of the problem of		□ 0000750 Delayed speech and language development □ 0002376 Developmental regression □ 0001263 Global developmental delay □ 0001249 Intellectual disability □ 0002187 Profound □ 0010864 Severe □ 0002342 Moderate □ 0001276 Mild □ 0001270 Motor delay □ MUSCULOSKELETAL □ 0002804 Arthrogryposis multiplex congenita □ 0003199 Decreased muscle mass □ 0001371 Flexion contracture □ 0001528 Hemihypertrophy □ 0001252 Hypotonia □ 0001276 Hypertonia □ 0001382 Joint hypermobility		
☐ 0001518 Small for gestational age	□ 0012460	Generalized clonic	С	☐ 0002808 Kyphosis	-	
STRUCTURAL BRAIN ABNORMALITIES 0002134 Abnormality of basal ganglia 0002363 Abnormality of the brain stem 0001273 Abnormality of corpus callosum 0002269 Abnormality of neuronal migration 0007360 Aplasia/hypoplasia of the cerebellum 0012444 Brain atrophy 0007266 Cerebral dysmyelination 0006808 Cerebral hypomyelination	□ 0002069 □ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■	□ 0002069 Tonic-clonic □ 000 ■ 000 □ 000 METABOLIC □ 000 □ 0001941 Acidosis □ 000 □ 0003234 Decreased plasma carnitine □ 000 □ 0003348 Hyperalaninemia □ 000 □ 0001943 Hypoglycemia □ 000 □ 0001987 Hyperammonemia □ 000 □ 0002490 Increased CSF lactate □ 000 □ 0003542 Increased serum pyruvate □ 000 □ 0001946 Ketosis □ abr □ 0003128 Lactic acidosis □ 000				
 □ 0002500 Cerebral white matter abnormality □ 0002539 Cortical dysplasia □ 0002282 Heterotopia □ 0001360 Holoprosencephaly □ 0000238 Hydrocephalus □ 0002352 Leukoencephalopathy □ 0001339 Lissencephaly 	☐ Abnormal n ☐ DEVELOPMEN ☐ 0007018 At hyperactivit	rganic aciduria ewborn screen ITAL/BEHAVIORA tention deficit ty disorder utistic spectrum d	L isorder	CRANIOFACIAL □ 0000271 Abnormal fac □ 0000306 Abnormality (□ □ 0000290 Abnormality (□ □ 0000175 Cleft palate □ 0410030 Cleft lip □ 0001363 Craniosynost □ 0000286 Epicanthus □ 0000316 Hypertelorisr M-1022, Rev 7 October 20	of the nose of the forehead tosis	

□ 0000601 Hypotelorism □ 0000256 Macrocephaly	□ 0002205 Recurrent respiratory infections	□ 0001597 Nail abnormality□ 0001581 Recurrent skin infections
□ 0000252 Microcephaly	□ 0002878 Respiratory failure	
EYE AND VISION 0000526 Aniridia 0000528 Anophthalmia 0000618 Blindness	 □ 0002093 Respiratory insufficiency □ 0002107 Pneumothorax □ 0002206 Pulmonary fibrosis □ 0002575 Tracheoesophageal fistula □ 0002779 Tracheomalacia 	HEMATOLOGY AND IMMUNOLOGY □ 0001928 Abnormality of coagulation □ 0004432 Agammaglobulinemia □ 0001903 Anemia □ 0031020 Bone marrow
□ 0000589 Coloboma		hypercellularity
□ 0000519 Congenital cataract	GASTROINTESTINAL	□ 0001878 Hemolytic anemia
□ 0000568 Microphthalmia	☐ 0002251 Aganglionic megacolon	□ 0002721 Immunodeficiency
□ 0000639 Nystagmus	☐ 0002910 Elevated hepatic	□ 0001888 Lymphopenia
□ 0000648 Optic atrophy	transaminase .	□ 0001875 Neutropenia
□ 0000508 Ptosis	□ 0001508 Failure to thrive	□ 0001876 Pancytopenia
□ 0009919 Retinoblastoma	□ 0001543 Gastroschisis	□ 0002719 Recurrent infections
□ 0000486 Strabismus	☐ 0001399 Hepatic failure	☐ 0004430 Severe combined
□ 0000505 Visual impairment	□ 0002240 Hepatomegaly	immunodeficiency
	□ 0002021 Pyloric stenosis	☐ 0001873 Thrombocytopenia
	□ 0001744 Splenomegaly	
EAR AND HEARING	□ 0002013 Vomiting	
□ 0000377 Abnormal external ear		ENDOCRINE
□ 0000405 Conductive hearing		☐ 0000834 Abnormality of adrenal
impairment	GENITOURINARY	glands
□ 0000410 Mixed hearing impairment	☐ 0000812 Abnormal internal genitalia	□ 0008226 Androgen insufficiency
□ 0000407 Sensorineural hearing	□ 0000062 Ambiguous genitalia	☐ 0008258 Congenital adrenal
impairment	□ 0000028 Cryptorchidism	hyperplasia
	□ 0000085 Horseshoe kidney	□ 0000819 Diabetes mellitus
CARDIAC	□ 0000126 Hydronephrosis	□ 0000873 Diabetes insipidus
☐ 0001713 Abnormal cardiac ventricle	□ 0000047 Hypospadias	□ 0001738 Exocrine pancreatic
□ 0002616 Aortic root dilatation	□ 0008738 Partially duplicated kidney	insufficiency
□ 0011675 Arrhythmia	☐ 0000113 Polycystic kidney dysplasia	□ 0000821 Hypothyroidism
□ 0001631 Atrial septal defect	□ 0000107 Renal cyst	☐ 0000829 Hypoparathyroidism
□ 0001647 Bicuspid aortic valve	□ 0000104 Renal agenesis	□
□ 0001638 Cardiomyopathy	□ 0000089 Renal hypoplasia	CANCER
□ 0001680 Coarctation of aorta	□ 0000069 Ureter abnormality	☐ Type of cancer
□ 0001642 Pulmonary stenosis	☐ 0000795 Urethra abnormality	
□ 0001636 Tetralogy of Fallot	o	☐ Age of diagnosis
□ 0001629 Ventricular septal defect	SKIN AND HAIR	☐ Family history of cancer and affected
	□ 0008066 Blistering of skin	relatives
	□ 0000957 Café-au-lait spot	
RESPIRATORY	☐ 0005306 Capillary hemangioma	
□ 0002104 Apnea	□ 0001595 Hair abnormality	OTLIER
□ 0002883 Hyperventilation	□ 0000974 Hyperextensible skin	OTHER
□ 0002791 Hypoventilation	☐ 0000953 Hyperpigmentation of skin	-
□ 0008751 Laryngeal cleft	□ 0000998 Hypertrichosis	
□ 0001601 Laryngomalacia	☐ 0001010 Hypopigmentation of skin	
	☐ 0008066 Ichthyosis	

PREVIOUS TESTIN	IG (provide copy of a	bnormal result		
Echocardiogram:	☐ Not performed	☐ Normal	□ Abnormal	
EEG:	☐ Not performed	☐ Normal	□ Abnormal	
EMG/NCV:	☐ Not performed	☐ Normal	☐ Abnormal	
Gene testing:		☐ Normal	□ Abnormal	
Gene testing:		☐ Normal	□ Abnormal	
Karyotype:	☐ Not performed	□ Normal	□ Abnormal	
Downstal was :				
Prenatal genomic	microarray: ☐ Not performed	□ Normal	☐ Abnormal	
Dantmatal may :	:			
Postnatal genomic	□ Not performed	□ Normal	□ Abnormal	
MDI (huain).	□ Nat wastawaad	□ Na was al	□ Aba award	
MRI (brain):	□ Not performed	□ Normal	□ Abnormal	
MRI (other):	☐ Not performed	☐ Normal	□ Abnormal	
CT (brain):	□ Not performed	□ Normal	□ Abnormal	
CT (other):	\square Not performed	□ Normal	☐ Abnormal	
Muscle biopsy:	☐ Not performed	☐ Normal	□ Abnormal	
Ultrasound:	☐ Not performed	☐ Normal	☐ Abnormal	
X-ray:	☐ Not performed	□ Normal	☐ Abnormal	
	-			
Other test:		☐ Normal	☐ Abnormal	
Other test:		□ Normal	□ Abnormal	
Other test:		□ Normal	☐ Abnormal	